

REMARKS

As an initial point, Applicants express their gratitude to Examiner Wessendorf for the courtesies extended on the Examiner Interview of March 1, 2004 where the 35 U.S.C. §112 rejections of all the claims were discussed. Applicants argued that the claims have sufficient written description as the claims are directed to methods of detecting modification of biomolecules and no biomolecules, *per se*, are being claimed.

Prior to the present amendment, claims 1-3, 5-22, and 33-34 were pending in the present application. By the present amendment, claims 2 and 3 have been canceled without prejudice or disclaimer of the subject matter therein and claim 35 has been added. Therefore, claims 1, 5-22, 27, and 33-35 are pending in the present application. Claims 8-22 are withdrawn from consideration.

Claim 1 has been amended to recite the step of placing a polymer gasket having holes on the substrate. Support for this element can be found on page 9, paragraph 21. Claim 1 has also been amended to recite that the holes have a size and orientation of wells of a 96-well, 384-well, 1536-well, or 3456-well microwell plate. Support for this element can be found on page 24, paragraph 56. Claim 1 has also been amended to recite that the tyrosine kinases are immobilized on the substrate and that the tyrosine kinases are exposed to members of the src family of kinases and ATP in solution. Support for this element can be found on page 60, paragraph 128 (example 1). Support for new claim 35 can be found on page 61-62, paragraph 133 (Example 3).

In the Office Action, all the claims were rejected as allegedly lacking sufficient written description. Claims 1, 7, 23-29, and 32 were rejected as allegedly being indefinite. Claims 1-3, 5-7, 27 and 33-34 were rejected under 35 U.S.C. 102(e) as being anticipated by or in the alternative under 35 U.S.C. 103(a) as being rendered obvious by U.S. Patent Application Publication 2001/0053520 to Borrebaeck (Borrebaeck). Claims 1-3, 5-7, 27 and 33-34 were rejected under 35 U.S.C. 102(a) as being anticipated by or rendered obvious by U.S. Patent No. 6,232,066 to Felder ("Felder").


Applicants submit that the present claims have sufficient written description, are definite, and are not anticipated or rendered obvious by Borrebaeck or Felder. Namely, claims 1, 5-7, 27, and 33-35 recite specific immobilized biomolecules and specific

biomolecules in solution as described and detailed in Examples 1 and 3 of the present application. The present claims also recite that a "gasket having holes" is placed on the substrate as specifically disclosed on page 9, paragraph 21. Furthermore, neither Borrebaeck and Felder, alone or in combination teach each and every element of the claims. Specifically, there is no mention in either reference of arraying biomolecules by placing a polymer gasket on the substrate wherein the holes have the size and orientation of wells of a standard microtiter plate. Accordingly, Applicants respectfully request withdrawal of all the rejections.

It is respectfully submitted that the present application is now in condition for allowance, which action is respectfully requested. The Examiner is invited to contact Applicant's representative to discuss any issue that would expedite allowance of the subject application. Any fees for extension(s) of time or additional fees that are required in connection with the filing of this response, such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and the Commissioner is authorized to charge any such required fees or to credit any overpayment to Kenyon & Kenyon's Deposit Account No. 11-0600.

Respectfully submitted,
KENYON & KENYON

Dated: April 2, 2004


By Zeba Ali
(Reg. No. 51,392)

1500 K Street, N.W.
Washington, D.C. 20005
Tel: (202) 220-4200
Fax: (202) 220-4201

488538v.1